TVTX — Travere Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $5.09bn
- $490.73m
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-BlackRock, MDA Space, Revolution Medicines
U.S. STOCKS ON THE MOVE-Bloom, J&J, CarMax
U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
Travere jumps after US FDA approves expanded use of kidney disease drug
NASDAQ RESUMED AT 07:55 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (updated)
Brief: Travere Therapeutics Announces Full FDA Approval Of Filspari® (Sparsentan), The First And Only Approved Medicine For Fsgs
US FDA expands approval for Travere Therapeutics' drug for rare kidney disease
NASDAQ TRADE HALT HALT NEWS PENDING AT 05:33 PM
Travere Q4 product sales surge on FILSPARI growth
Brief: Travere Therapeutics Q4 EPS USD 0.03
NASDAQ RESUMED AT 03:30 PM
US FDA extends review of Travere’s drug for rare kidney disease (updated)
US FDA extends review of Travere’s drug for rare kidney disease
Brief: Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS
NASDAQ TRADE HALT HALT NEWS PENDING AT 12:40 PM
Travere Therapeutics slides after forecasting Q4 sales below estimates